TYLER, Texas—ENvue Medical, a commercial-stage medical device company, announced a new distribution agreement with Peak Medical, a complete medical equipment solutions company, to expand commercial distribution of ENvue’s UroShield device across the United Kingdom and the Republic of Ireland.
The agreement includes minimum purchase commitments of approximately $2.6 million over its initial term through Monday, Dec. 31, 2029.
“UroShield helps patients avoid painful, recurring catheter-associated infections and our agreement with Peak Medical gives the device a broader path to the patients and providers who can benefit from it,” said Doron Besser, CEO of ENvue Medical. “The multi-year minimum purchase commitment under this agreement provides an important foundation for accelerating UroShield’s commercial growth in these markets. This agreement also demonstrates how we are pursuing multiple growth opportunities across our portfolio, including expanding distribution of our established NanoVibronix products while continuing to advance the ENvue platform.”
Under the agreement, Peak Medical will serve as the exclusive distributor of UroShield in the United Kingdom and the Republic of Ireland through Monday, Dec. 31, 2029, with an option to renew for an additional three-year period. The agreement includes increasing annual minimum purchase commitments, with product volumes growing from 650 units in 2026 to 35,000 units in 2029. In aggregate, the minimum purchase commitments represent approximately £2.1 million, or approximately $2.6 million, over the initial three-year term.
The NanoVibronix product line comprises the Company’s acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology and are designed for use in home or care settings.